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Abstract
Background: Staphylococcus aureus, a leading cause of mastitis in dairy cattle, causes severe mastitis and/or chronic
persistent infections with detrimental effects on the cows’ wellbeing, lifespan and milk production. Despite years of
research there is no effective vaccine against S. aureus mastitis. Boosting of non-protective pre-existing immunity to
S. aureus, induced by natural exposure to S. aureus, by vaccination may interfere with vaccine efficacy. The aim was
to assess whether experimental immunization of S. aureus naïve animals results in an immune response that differs
from immunity following natural exposure to S. aureus.
Results: First, to define the period during which calves are immunologically naïve for S. aureus, Efb, LukM, and
whole-cell S. aureus specific serum antibodies were measured in a cohort of newborn calves by ELISA. Rising S.
aureus specific antibodies indicated that from week 12 onward calves mounted an immune response to S. aureus
due to natural exposure. Next, an experimental immunization trial was set up using 8-week-old heifer calves (n= 16), half
of which were immunized with the immune evasion molecules Efb and LukM. Immunization was repeated after one year
and before parturition and humoral and cellular immunity specific for Efb and LukM was determined throughout the
study. Post-partum, antibody levels against LukM and EfB were significantly higher in serum, colostrum and milk in the
experimentally immunized animals compared to animals naturally exposed to S. aureus. LukM specific IL17a responses
were also significantly higher in the immunized cows post-partum.
Conclusions: Experimental immunization with staphylococcal immune evasion molecules starting before natural
exposure resulted in significantly higher antibody levels against Efb and LukM around parturition in serum as well as the
site of infection, i.e. in colostrum and milk, compared to natural exposure to S. aureus. This study showed that it is
practically feasible to vaccinate S. aureus naïve cattle and that experimental immunization induced a humoral immune
response that differed from that after natural exposure only.
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Background
Intramammary infections with Staphylococcus aureus
(SA) are common in cattle and often lead to severe mas-
titis and/or chronic persistent infections with detrimen-
tal effects on the cows’ wellbeing, lifespan and milk
production [1, 2]. The pathogenesis of S. aureus mastitis
involves the attachment of S. aureus to epithelial cells
[3], followed by the production of a range of immune
evasion molecules which severely impede effective tar-
geting of S. aureus by the immune system [4–8]. In
addition, cell invasion and biofilm formation decreases
antibiotic effectivity, resulting in partial clearance and
increased antibiotic resistance [4, 9, 10]. The ineffective
treatment of S. aureus mastitis often leads to chronic in-
fections, therefore, prevention of S. aureus infection by
vaccination is highly desirable [11, 12]. However, despite
numerous attempts and the use of various vaccine anti-
gens, todays available vaccines against S. aureus only re-
sult in limited protection [13–15]. Pre-existing immunity
may influence the response to vaccination [16–18]. The
majority of dairy cattle have pre-existing immunity
against S. aureus at first calving due to natural exposure
to S. aureus during rearing (e.g. through (transient)
colonization), as evidenced by high antibody titers
against S. aureus and several of its secreted immune eva-
sion proteins [19–21]. The existing immune response
against S. aureus seems to be non-protective, since in-
fection with S. aureus does not protect against subse-
quent infections [22–25]. We therefore hypothesize that
vaccination of non-naïve cows may lead to boosting of
the existing non-protective immune response rather
than the induction of a protective immune response.
Understanding the dynamics of immunity induced fol-
lowing natural exposure to S. aureus in young calves will
help to determine the period during which dairy calves
are still naïve for S. aureus.
The aim of the present study was to investigate
whether it is feasible to vaccinate S. aureus naïve animals
and whether experimental immunization of S. aureus
naïve animals results in a different immune response
compared to immunity induced by natural exposure to
S. aureus. We have previously reported a high preva-
lence of antibodies against the S. aureus immune evasion
proteins extracellular fibrinogen-binding protein (Efb)
and the leukocidin subunit LukM in dairy cows [19]. Efb
forms a shield of host proteins around the bacterium,
helping S. aureus escape from phagocytic cells [26],
while LukM is the receptor binding subunit of the
bi-component leukocidin LukMF’, a potent toxin with an
important role in S. aureus mastitis [27–29]. First, to de-
termine the time period when S. aureus naïve animals
can be vaccinated the kinetics of maternal immunity and
the onset of immunity against S. aureus following nat-
ural exposure were studied by measuring Efb, LukM and
whole-cell S. aureus specific antibodies in a cohort of
new-born calves. Secondly, young calves were immu-
nized with an experimental vaccine containing recom-
binant Efb and LukM, prior to the development of
immunity to S. aureus due to natural exposure, and the
development of humoral and cellular immune responses
were measured for two years up until the first
post-partum period. These responses were compared to
the immune responses following natural exposure to S.
aureus. Experimental immunization starting before nat-
ural exposure to S. aureus resulted in significantly higher
antibody levels against Efb and LukM around parturition
in serum as well as in colostrum and milk, i.e. at the site
of infection, compared to natural exposure.
Methods
Study design
All procedures and treatments were approved by the
Ethical Committee for Animal Experiments of Utrecht
University (Permit No. DEC0202080601 and Permit No.
2012.II.09.136) and performed according to national and
European regulations. After the described studies, all an-
imals were kept alive and either joined the teaching dairy
herd, were reared until sent for slaughter or were reused
for other animal experiments.
To study antibody dynamics due to natural exposure
to S. aureus and its secreted evasion proteins (Study 1),
22 pregnant Holstein-Friesian (cross) heifers, purchased
from commercial farms or reared at the research facility,
were housed at the research facilities of the Faculty of
Veterinary Medicine, Utrecht University (Utrecht, The
Netherlands) in 2004. Heifers were housed in tie-stalls
on rubber mats covered with sawdust and were fed ac-
cording to their requirements with roughage and con-
centrates, while water was available ad libitum. General
health was inspected on a daily basis. Heifers were ob-
served by camera to monitor for signs of calving. All
calvings were supervised and assisted when necessary.
Calves were separated from their dams directly after
birth to collect a pre-colostral blood sample. Calves were
fed colostrum from their own dam after the first blood
sampling. The first colostrum feeding was performed as
soon as the calf was able to stand and swallow. Subse-
quent feedings were performed at 6–8 h intervals and
aimed to feed calves a total of 4–6 l of colostrum during
the first 24 h by spontaneous uptake.
For the experimental immunization study (Study 2) 16
Holstein-Friesian or Holstein-Friesian cross heifer calves
were purchased from commercial farms with a mean age
of three weeks (+/− 1 week) in autumn 2013. Calves
were housed in groups of four animals on straw bedding
at the Faculty of Veterinary Medicine and fed milk re-
placer, concentrates and roughage according to their re-
quirements. In Spring/Summer 2014 and 2015 heifers
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were kept as a herd on pasture. In autumn, winter and
spring heifers were housed in tie-stalls and were enrolled
in a timed artificial insemination protocol to synchronize
gestation. In the autumn of 2015 the heifers calved at
the research facility. Heifers were observed during calv-
ing and assisted when necessary. Colostrum was milked
from each quarter of the dam and a mixed colostrum
sample was stored at − 20 °C until further analysis. Gen-
eral health was inspected on a daily basis. Around three
months of age all animals had mild respiratory prob-
lems, six animals were treated with NSAID’s. Around 14
months of age all animals had medium to severe respira-
tory problems. All animals were treated with NSAID’s
and seven animals were treated with antibiotics adhering
to national good veterinary practice protocols on the use
of antibiotics.
At the start of the experimental immunization trial,
heifer calves were assigned to one of four treatment
groups (Table 1) using block randomization. After an
acclimatization period of two to three weeks animals
were immunized at six weeks of age (+/− 1 week) ac-
cording to the scheme in Table 1, with an experimental
vaccine containing the recombinant secreted immune
evasion proteins LukM and Efb (Prime). Three booster
immunizations were administered, the first six weeks
after prime (B1), the second 52 weeks later (B2) and the
third two weeks before the expected calving date (B3),
which was around 99 weeks after the prime. Subcutane-
ous (SC) immunization was carried out in the midline of
the inguinal region at the future location of the udder
using a 2 mL syringe (Omnifix, Braun, Melsungen,
Germany) with a 21G needle (Terumo Europe N.V.,
Leuven, Belgium). Intranasal (IN) application was per-
formed using a nasal spray pump directly into the nostril
which produced an aerosolized inoculum with a wide
droplet size range. Adjuvant (Adj) only vaccine was ad-
ministered intranasally at Prime and subcutaneously at
the same site as for the SC group for the booster
immunizations.
The study was originally designed to compare the im-
mune response following both IN and SC immunization
to immunity following natural exposure to S. aureus.
However, analysis of immune responses following the
first booster immunization showed that there was no
detectable antibody response following IN immunization
(Additional file 1). In a concurrent study where cows
were immunized with the same experimental vaccine
there was also no detectable antibody response following
IN immunization [19]. Antibody and cytokine responses
between the IN/IN and Adj/Adj groups and between the
IN/SC and SC/SC groups were comparable at week 7
(Additional file 2). Therefore, the IN immunization route
was dropped and from B2 onwards groups were com-
bined; heifers of the IN/IN group were added to the
Adj/Adj group and received adjuvant only subcutane-
ously at B2 and B3, while animals of the IN/SC group
reacted similarly to the SC/SC group and received the
experimental vaccine at B2 and B3 subcutaneously.
Leaving only two groups: an experimental immunization
group (SC) and a natural exposure control group (Adj)
(Table 1). Twelve of the sixteen heifers were successfully
inseminated and could therefore be immunized before
parturition (B3) (6 Adj; 6 SC). The four non-pregnant
animals were removed from the study from week 56 on-
wards. All data were analyzed according to the experi-
mental immunization and natural exposure control
group only, starting from time point zero.
Vaccine composition and recombinant proteins
The experimental vaccine, consisting of an oil-in-water
adjuvant combined with an alginate hydrogel (proprietary
adjuvant, MSD-AH), contained 50 μg S. carnosus derived
recombinant Efb and 50 μg E. coli derived LukM per dose.
For the prime and first booster immunization (B1) 5 μg
Cholera toxin (Sigma-Aldrich Chemie B.V., Zwijndrecht,
The Netherlands), a mucosal adjuvant, was added to en-
hance mucosal immunity [30]. Since no intranasal (i.e.
mucosal) immunization was carried out at immunizations
B2 and B3, Cholera toxin was not included.
Recombinant Efb and LukM expressed in E. coli were
generated as described previously [19] and were used for
all assays. At week 0 recombinant Efb protein was not
available and could, therefore, not be used in the cell
based assays in that week. To produce the S. carnosus
derived Efb used for the vaccine, the gene encoding efb
from the S. aureus Newbould305 strain (ATCC29740)
was amplified by PCR and ligated into a pXR100 derived
vector and transfected into S. carnosus. S. carnosus cul-
ture supernatant was filtered with a 0.2 μm filter, ana-
lyzed on gel for Efb purity and concentration, and stored
at − 20 °C.
Sample collection and preparation
In study 1 colostrum and serum was collected directly
after parturition of enrolled heifers and of prenatal
calves a serum sample was obtained before colostrum
was administered. Further serum samples of the calves
were taken one week after parturition and at week 5, 12,
Table 1 Experimental immunization scheme of study 2
Prime
(Week 0)
B1
(Week 6)
B2
(Week 52)
B3
(~Week 101)
Group 1 (n = 4) SC SC
SC SC
Group 2 (n = 4) IN
Group 3 (n = 4) IN IN
Adj (SC) Adj (SC)
Group 4 (n = 4) Adj (IN) Adj (SC)
B1, B2, B3 – Booster immunization 1, 2, 3; SC – Subcutaneous route; IN –
Intranasal route; Adj – Adjuvant only immunization
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23 and 29 of life. In study 2 blood samples were collected
before the first immunization (week 0), at week 7, 52, 56,
~ 99 (two weeks before predicted parturition date) and ~
103 (two weeks after predicted parturition date).
Blood was collected from the jugular vein in animals
up to one year of age. In older animals the coccygeal
vein was used. A sterile blood collection system was
used to collect blood in Li-heparin and serum tubes
(Vacutainer, Becton Dickinson or Vacuette, Greiner
Bio-One). After coagulation serum samples were centri-
fuged for 20 min at 1500 x g to collect serum. Colostrum
samples were collected directly after calving from all 4
quarters. Milk samples were collected of all 4 quarters at
the morning milking. Colostrum and milk samples were
centrifuged for 10 min at 1500 x g to obtain skimmed
colostrum/milk. Serum, colostrum and milk samples
were stored at − 20 until further analysis.
Total white blood cells (WBC) were isolated by lysing
erythrocytes using ammonium-chloride-potassium lysis
buffer.
Antibody ELISA
LukM, Efb and S. aureus whole-cell specific IgG1 and
IgG2 antibodies in serum, colostrum and milk were deter-
mined by ELISA. Because S. aureus may express Protein
A, which leads to non-specific binding of antibodies, the
Protein A negative Reynolds strain was used for the
whole-cell ELISA [31]. The Reynolds strain was grown in
trypticase soy broth at 39,5 °C and after 20 h bacteria were
inactivated with 0,5% formalin overnight. For LukM, Efb
and S. aureus whole-cell antibody detection, microtiter
plates (NUNC MaxiSorp™, eBioscience, Affymetrix, Santa
Clara, USA) were coated with 1.25 μg/ml, 1.0 μg/ml and
1 μg/well antigen in 0.05M sodium-bicarbonate buffer, re-
spectively. Plates were blocked using Blocking buffer
(‘Blocking reagent for ELISA’, Roche Diagnostics GmbH,
Germany), except for the LukM ELISA for study 1 which
were blocked in fat free milk powder (Elk melk, Friesland-
Campina, Amersfoort, The Netherlands) and for the S.
aureus whole-cell ELISA blocking was done with 24 μg
casein/well. Serum, milk and colostrum samples were
tested in duplicate according to the dilutions shown in
Additional file 3. Monoclonal mouse anti-bovine IgG1
and IgG2 (Prionics Lelystad B.V., Life Technologies,
Thermo Fisher Scientific) were used as secondary anti-
bodies. Bound secondary antibodies were detected using
horseradish conjugated goat anti-mouse-IgG (Biolegend,
San Diego, USA). Finally, Tetramethylbenzidine (TMB;
Pierce™, Life Technologies, Thermo Fisher Scientific) was
used as a substrate and reactions were stopped by adding
4 N sulphuric acid. Extinctions (450 nm) were measured
on a Multiscan™ FC Microplate Photometer (Thermo
Fisher Scientific) within 5–20min depending on the spe-
cific ELISA.
In order to standardize results and to compare results
between plates, positive control serum samples were in-
cluded in quadruplicate in all ELISA’s and sample to
positive ratios were calculated as (sample-buffer con-
trol)/(positive-buffer control).
Whole blood stimulation
RPMI 1640 (Gibco), supplemented with Glutamax™, 50
IU/ml Penicillin, 50 μg/ml Streptomycin, 50uM
β-mercaptoethanol and 10% FCS, was used as culture
medium. 500 μL heparinized blood was added to 500 μL
culture medium with antigens, resulting in a final concen-
tration of Efb and LukM of 10 μg/ml. The negative control
was culture medium only and Concanavalin A at 2,5μg/ml
was used as a positive control. Whole blood was incubated
at 37 °C and 5% CO2 in a humidified incubator. After 48
or 72 h supernatants were collected from separate assays
for the interferon-γ (IFN-γ) and Interleukin-17a (IL17a)
ELISA, respectively, and stored at − 20 C.
Proliferation
WBC were washed in PBS and subsequently stained with
Carboxyfluorescein succinimidyl ester (CFSE; Thermo
Fisher Scientific) at 0.625–1.25 μM for 5 min at 37 C.
Stained WBC were washed twice in culture medium and
resuspended in culture medium in a volume equal to the
original blood volume. Next, 500 μL CFSE stained WBC
were added to 500 μL culture medium with or without
antigens, as for the whole blood stimulation. After 96 h
incubation at 37 °C and 5% CO2 in a humidified incuba-
tor, cells were harvested, washed in FACS buffer (FB;
PBS supplemented with 2% FCS and 0.01% sodium
azide) and stained with mouse monoclonal antibodies
against bovine CD4 (CC8-Alexa Fluor® 647, AbD Sero-
tec, Kidlington, UK) or with mouse anti-CD8 (CC63-A-
lexa Fluor® 647, AbD Serotec) and mouse anti-TCR1/
N24 (GB21A-Alexa Fluor® 405, VMRD, Pullman, Wash-
ington, USA), a gamma delta T-cell marker. The
anti-TCR1/N24 antibody was conjugated with Zenon®
anti-mouse IgG2b-Alexa Fluor® 405 Fab fragment
(Thermo Fisher Scientific). Cells were incubated for 20
min at 4 °C in the dark and washed twice with FB before
being acquired on a FACS Canto II (Becton Dickinson
Immunocytometry Systems, San Jose, California, USA).
Intracellular cytokine staining
WBC were washed and resuspended in culture medium in
a volume equal to half of the original blood volume.
500 μL WBC suspension was added to 500 μL culture
medium with or without antigens, as for the whole blood
stimulation. After a six day incubation period, PMA (50
ng/ml, Sigma-Aldrich) and Ionomycin (1 μg/ml,
Sigma-Aldrich) were added to the cells. After a further 1 h
incubation Brefeldin A (10 μg/mL; Sigma-Aldrich) was
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added to each well and incubation was continued for an-
other 5 h. Cells were harvested and washed once in FB
and divided for intracellular IFN-γ and IL17a staining.
First cells were incubated for 20min at 4 °C in the dark
with mouse monoclonal antibodies against bovine CD4
(CC8-Alexa Fluor® 647, AbD Serotec, Kidlington, UK) and
CD8 (CC63-PE, AbD Serotec). Cells were washed and
fixed and permeabilized using Cytofix/Cytoperm and
Perm/Wash method (Becton Dickinson) according to
manufacturer’s instructions. Subsequently cells were
stained with a biotinylated anti-bovine IFN-γ monoclonal
antibody (6C3; BioSource, San Diego, California, USA) or
biotinylated anti-bovine IL17a polycolonal antibodies
(Kingfisher Biotech, Inc.) for 30min at 4 °C in the dark.
Next, cells were incubated with streptavidin-eFluor450
(eBioscience, Vienna, Austria) for 30min at 4 °C in the
dark. After two washing steps with Perm/Wash solution,
samples were resuspended in FB and acquired on a FACS
Canto II.
Cytokine ELISA
Supernatants from the 48 h and 72 h whole blood stimu-
lation assay were analyzed for the presence of
interferon-γ (IFN-γ) and Interleukin-17a (IL17a), re-
spectively. IFN-γ was detected using the Bovigam ELISA
(Prionics) according to the manufacturer’s protocol. Re-
sults were expressed as sample to positive ratio. IL17a
was detected by a quantitative ELISA. Microtiter plates
(EIA/RIA Costar™) were coated overnight at 4 °C with
2 μg/mL rabbit-α-bovine IL17a polyclonal antibody
(Kingfisher Biotech, Inc., Saint Paul, Minnesota, USA) in
50 μl in 0.05M sodium-bicarbonate buffer. Plates were
blocked using Blocking buffer and supernatant samples
diluted 1:2 in Blocking buffer were added in triplicate
and incubated at room temperature for 2 h. Standard
curves of recombinant bovine IL17a protein (Kingfisher
Biotech, Inc.), ranging from 15.6–1000 pg/mL, were in-
cluded in triplicate on each plate. For detection a bio-
tinylated rabbit-α-bovine polyclonal antibody (0.5 μg/
mL) was added and incubated for 30 min at room
temperature. Bound antibodies were detected using
streptavidin-PolyHRP80 (100 ng/mL) for 20 min at room
temperature. The ELISA’s were continued as for the
antibody ELISA’s. Standard curves were used to calculate
the IL17a concentrations from the absorbance values.
Data analysis and statistics
Flow cytometry data were analyzed using Flowjo soft-
ware (TreeStar Inc.). Live cells were selected based on a
forward sideward scatter gate. Additional file 4 shows
the flow cytometry gating strategy. For graphical presen-
tation of the data GraphPad Prism (GraphPad Software
Inc. 6.01, La Jolla, USA) was used and all figures show
mean with SEM. Proliferation data and data from the
whole blood stimulation were normalized using a log
transformation. Descriptive- and statistical analyses were
performed in Graphpad Prism or Excel (Microsoft office
2010, Microsoft, Redmond, USA) with animal as the ex-
perimental unit. Results were analyzed using unpaired
two-sided T-tests corrected for unequal variances. To
correct for multiple comparisons, p-values were adjusted
using the step-down Holms-Bonferroni method. Ad-
justed P-values < 0.05 were considered significant.
P-values < 0.05 that were not significant after the mul-
tiple comparisons correction were considered a trend.
Results
Dynamics of Staphylococcus aureus specific antibodies in
newborn calves
At parturition all dams had detectable IgG1 and IgG2
antibodies against whole-cell S. aureus and the secreted
proteins LukM and Efb in serum (Additional file 5) as well
as colostrum (Fig. 1). Before colostrum intake all calves
had virtually no detectable antibodies specific for S. aur-
eus, LukM and Efb (Fig. 1). Following absorption of ma-
ternal antibodies from colostrum, antibody levels in the
calves increased steeply, with serum IgG1 levels exceeding
that of their respective dams. The IgG1 concentration in
colostrum is much higher than the IgG2 concentration
[32] and therefore calf serum IgG2 antibody levels did not
increase as much relative to the maternal antibody levels.
Colostrum antibody levels correlated reasonably well with
dam serum levels, especially for the single antigens, with
R2s ranging from 0.21–0.85, whereas for whole-cell S. aur-
eus the R2 was between 0.17 and 0.32 (Additional file 5).
As expected, colostrum antibody levels correlated with
calf serum antibody levels following colostrum intake,
with R2s ranging from 0.34–0.79, except for whole-cell S.
aureus specific IgG1 antibody levels which had and R2 of
0.03 (Additional file 5). However, the colostrum IgG1
levels were in the upper range of the ELISA, lowering the
correlation.
Once taken up by the calf, maternal antibodies are used
and degraded. This was reflected by declining antibody
levels in the calves between week 1 and week 12 (Fig. 1),
which was most apparent for the IgG1 antibody levels.
From week 12 onwards IgG1 and IgG2 levels started ris-
ing, which was especially clear for IgG2 due to the low ini-
tial IgG2 levels. Overall IgG1 and IgG2 antibodies specific
for whole-cell S. aureus, LukM and Efb showed the same
dynamics. The results indicate that due to natural expos-
ure to S. aureus the calves mounted a humoral immune
response against S. aureus around 12 weeks of age.
Antibody responses induced by experimental
immunization
Serum ELISA pre-immunization showed that the calves
enrolled in the experimental immunization study had
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Fig. 1 Dynamics of Staphylococcus aureus specific antibodies following natural exposure. IgG1 (a, c, e) and IgG2 (b, d, f) antibodies specific for
whole SA bacterium (a, b), LukM (c, d) and EfB (e, f) measured in colostrum of dams and in serum of calves from before colostrum uptake until
week 29. S/P = Sample to positive ratio
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low antibody levels for LukM and Efb at 8 weeks of age.
After the prime and boost immunization antibody levels
rose in the experimental immunization group, with a
trend for higher levels compared to the natural exposure
control group at week 7 for LukM specific IgG1 and
IgG2 and Efb specific IgG1 (P < 0.05 before multiple
comparison correction, Figs. 2 and 3). Whereas the anti-
body levels dropped between week 7 and 52 in the ex-
perimentally immunized animals, antibody levels rose in
the control group, presumably because of natural expos-
ure to S. aureus between the first and second booster
immunization. Following the boost in week 52 antibody
levels rose slightly in the experimentally immunized ani-
mals, but were not significantly different from the con-
trol group. Two weeks post-partum, after the third
boost, antibody levels were significantly higher in the ex-
perimentally immunized animals for LukM specific IgG2
and Efb specific IgG1 and IgG2 and there was a trend
for higher levels for LukM specific IgG1 (Figs. 2 and 3).
Antibody levels in colostrum were significantly higher in
the experimentally immunized animals for both LukM
and Efb specific IgG1 and IgG2 (Figs. 2 and 3). LukM
and Efb specific IgG1 antibodies were also significantly
higher in milk two weeks post-partum (Figs. 2 and 3).
Cellular immune responses induced by experimental
immunization
The production of IFN-γ and IL17a was measured follow-
ing stimulation of whole blood with LukM and Efb. After
each immunization the IFN-γ production following LukM
stimulation rose and there was a trend for a higher pro-
duction compared to the control group in weeks 7 and 56
(Fig. 4a). IL17a production showed similar dynamics, with
a trend for higher IL17a levels at week 7 and significantly
higher levels post-partum compared to the control
group (Fig. 4c). IFN-γ production following Efb
stimulation increased after each immunization, but
was not significantly different from the control group
(Fig. 5a). Compared to the control group, IL17a pro-
duction was significantly higher in the experimentally
immunized animals in week 7 and there was a trend
for higher levels at week 56 (Fig. 5c).
After the prime and first booster immunization, in week
7, there was a trend for a higher proliferative response of
CD4 and CD8 T-cells following stimulation with LukM
(Fig. 4b, d). Between week 7 and 52 the proliferative re-
sponse declined in the experimentally immunized animals.
Following the second booster immunization, in week 56,
there was a trend for a higher CD4 proliferative response
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and the CD8 response was significantly higher in the ex-
perimentally immunized animals. Around parturition the
proliferative responses dropped and there were no differ-
ences between control and experimentally immunized ani-
mals. Differences in proliferative responses between the
control and experimentally immunized animals following
Efb stimulation were less pronounced (Fig. 5). There was a
trend for a higher proliferative response of CD4 T-cells in
week 7 (Fig. 5b). No differences in the proliferative response
of gamma delta T-cells were found between experimentally
immunized and control animals (Additional file 6).
Intracellular expression of IFN-γ and IL17a by CD4 and
CD8 T-cells was measured from week 52 onwards. Fol-
lowing stimulation for six days with LukM, both IFN-γ
and IL17a levels in CD4 and CD8 T-cells appeared to be
higher in the immunized animals in week 56, but this was
not significant (Additional file 7a,c,e,g). Intracellular cyto-
kine staining following Efb stimulation showed no effect
of experimental immunization (Additional file 7b, d, f, h).
Discussion
Staphylococcus aureus is one of the most common
causes of mastitis in dairy cattle and has a huge econom-
ical and welfare impact [1, 2], but despite years of research
there is currently no effective vaccine [13, 14].
Pre-existing non-protective immunity to S. aureus due to
natural exposure to S. aureus [22–25] may interfere with
vaccination. The present study showed that natural expos-
ure to S. aureus induced immune responses against S.
aureus at a very young age, i.e. from 12weeks of life on-
wards. Experimental immunization of calves with S. aur-
eus immune evasion proteins, starting before natural
exposure to S. aureus, resulted in significantly higher anti-
body levels against S. aureus immune evasion proteins
around parturition in serum, colostrum, and, milk com-
pared to natural exposure.
The neonatal calves enrolled in the first study had no
detectible antibodies specific for S. aureus before the ab-
sorption of maternal antibodies from colostrum.
Whereas the maternal antibody levels declined, the rise
in antibodies specific for both cell-wall and secreted
components of S. aureus from week 12 onward showed
that the calves mounted an immune response to S. aur-
eus following natural exposure at around 3months of
age. Since LukM and Efb are S. aureus specific, these
antibody responses were not a result of exposure to
other Staphylococci. Non-infected animals may acquire
S. aureus from many different sources, including the
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environment, animal contact and humans [33, 34]. An
immune response against S. aureus does not indicate
that the calves suffered from S. aureus related disease,
since many animals have been shown to be
non-symptomatic carriers of S. aureus on skin and mu-
cosa [33–35]. Nevertheless, the calves did mount an im-
mune response to Efb and LukM, proving that they were
exposed to these important virulence factors.
The aim of the experimental immunization study was to
test whether immunization of S. aureus naïve animals
changes the quality and quantity of the immune response
compared to natural exposure to S. aureus. Calves were
housed under the same conditions as the first study group
and the first immunization time point was chosen well be-
fore the expected rise in S. aureus specific antibodies as
seen during the first study. The low Efb and LukM specific
antibody levels at the start of the experiment and the rise
in antibody levels in the ‘natural exposure’ control group
between week 7 and week 52 both indicate that the calves
were immunized before natural exposure to S. aureus. Ini-
tially it was intended to compare the immune response
following natural exposure to both IN and SC
immunization. However, intranasal immunization did not
induce a measurable antibody response, which was also
seen in a concurrent study using the same experimental
vaccine [19]. In contrast to live vaccines [36], recombinant
proteins and adjuvant alone may not be enough to stimu-
late immune responses at the nasal mucosa. After the first
boost, immune responses were similar between the IN
and Adj groups and, although an effect of the IN or Adj
immunization cannot be excluded, it was therefore deter-
mined that for the purpose of this study the intranasally
immunized animals could be grouped together with the
adjuvant group for further analysis as a single natural
exposure group. Similarly, immune responses between the
IN/SC and SC group were comparable and these groups
were also combined into a SC immunization group.
Although this meant that for the experimental
immunization group half of the calves received three and
the other half received four immunizations, no significant
difference between the immunized animals were observed
(Additional file 2). From this it was inferred that it was
valid to compare the experimentally immunized animals
as one group to the control animals for the given readouts.
After the first booster immunization, there was a tendency
for higher antibody levels in the experimentally immu-
nized group, while there were no differences after the sec-
ond boost. The effect of the second booster may have
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been obscured by natural exposure to S. aureus which
(also) resulted in an antibody response in the control group.
Additionally, during the second boost the calves had mild
to severe respiratory disease, which may have suppressed
the response to experimental immunization. The third
boost just before parturition did result in significantly
higher IgG1 and IgG2 levels specific for Efb and LukM,
both systemically (serum) and locally in the udder (colos-
trum, milk) in the experimentally immunized animals.
Cellular immunity has been shown to be crucial in the
defense against S. aureus. For cattle, rapid recruitment of
neutrophils is believed to be vital in limiting S. aureus
mastitis [37]. In mice it has been shown that Th1 and
Th17 T-cells mediate protection against (intramammary)
S. aures infections [38–40]. Therefore, cell mediated adap-
tive immunity against the vaccine antigens was character-
ized. Overall, the cellular immune responses were low in
the experimentally immunized animals. The oil-in-water
adjuvant used is known to predominantly induce antibody
responses [41] and an alternative adjuvant would have
been more suitable to induce robust cell mediated im-
munity. A tendency for higher IFN-γ production and pro-
liferative response of CD4 and CD8 T-cells specific for
LukM of the experimentally immunized animals was
observed after the first and second boost. However, after
the third boost just before parturition there were no differ-
ences between the two groups, which may have been due
to the suppression of cell mediated immunity around par-
turition [42]. In contrast, there was a significantly higher
IL17a response to LukM after the third boost in the ex-
perimentally immunized cows. Inflammatory responses
(to S. aureus) in the udder have been associated with
IL17a responses [43–46] and neutrophil influx into the
udder of cattle immunized and challenged intramammary
with ovalbumin correlated with IL17a responses [47].
Th17 cytokines induce proinflammatory and cell mediated
immune response and are believed to play an important
role in host defense at mucosal sites [48]. Inducing IL17a/
Th17 responses may therefore play an important role in
protective intramammary immunity against S. aureus.
Besides pre-existing non-protective immunity to S.
aureus due to natural exposure, there may be several
other reasons why vaccination against S. aureus does not
induce a protective immune response. Whereas the
udder is the normal site of infection, most vaccines use
the parenteral route. Thus, immune cells and antibodies
have to pass the blood-udder barrier between the sys-
temic circulation and the udder tissue [32, 49, 50].
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Alternative immunization routes and adjuvant formula-
tions may result in increased local immunity [41, 51, 52],
but there is limited information of their effects on intra-
mammary immunity in cattle [19, 32, 53]. Inducing local
antibody responses in the udder by experimental
immunization has led to conflicting results [54–56]. In
cattle, local antibody production in the udder is ancillary
to translocation of antibodies from serum [32] and par-
ental immunization can increase antibody levels in the
milk [19, 53]. Experiments by Rainard et al. [57] demon-
strated that parenteral immunization can also lead to
strong cellular immune responses in the udder. In the
present study, repeated parenteral immunization starting
at a young age resulted in high S. aureus specific anti-
bodies both in colostrum and milk. Cows are particularly
susceptible to intramammary infections during the peri-
parturient period [58] and the high antibody levels in
the udder of the experimentally immunized animals both
during colostrogenesis (pre-partum) and post-partum in-
dicates that our immunization scheme can boost local
immunity during this critical period. Another hurdle in
inducing a protective immune response is the produc-
tion of a wide range of immune evasion factors by S.
aureus that target both the innate (e.g. phagocytosis,
complement) and adaptive (e.g. T-cells, antibodies) arms
of the immune system [59–61]. Therefore, although vac-
cination may induce an immune response against S. aur-
eus, this is not necessarily an effective response. We
have previously shown that the harmful effects of Efb
and LukMF’ can be neutralized by antibodies induced by
experimental immunization [19]. Including immune eva-
sion molecules in vaccines may induce antibodies that
neutralize their effects, allowing the immune system to
effectively target S. aureus. The immunization scheme
employed here induced high antibody levels specific for
S. aureus immune evasion molecules at the site of infec-
tion. Further research is necessary to examine the func-
tional capacity of the induced antibodies both in vitro
and in vivo.
Experimental immunization of S. aureus naïve calves
may skew the immune response against S. aureus towards
a protective immune response rather than the
non-protective immune response induced by natural ex-
posure. Here it was shown that immunization of S. aureus
naïve calves resulted in higher antibody levels specific for
S. aureus immune evasion factors, both systemically and
locally in the udder, as compared to animals naturally ex-
posed S. aureus. Additionally, immunization induced an
IL17a response against LukM, a cytokine that plays an im-
portant role in immunity against bacteria in the udder.
Experimental immunization of S. aureus naïve animals
was compared to natural exposure to S. aureus only.
Follow-up studies comparing different immunization regi-
mens followed by S. aureus challenge will be necessary to
address whether experimental immunization of S. aureus
naïve animals alters the quality of the immune response
compared to immunization of animals with non-protective
immunity due to natural exposure and whether this results
in protective immunity against S. aureus.
Conclusions
We showed that it is practically feasible to vaccinate S.
aureus naïve cattle and that experimental immunization
with staphylococcal immune evasion molecules results
in an immune response different from that induced by
natural exposure to S. aureus, leading to significantly
higher antibodies specific for S. aureus immune evasion
factors locally in the udder.
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